Since it was founded in 2006, KBP has worked closely with a variety of private and public companies and government agencies to enhance and refine the use of tobacco plants as a faster, less expensive and more efficient tool to produce recombinant proteins for biopharmaceutical research and for large-scale commercial production.
While these organizations are technically our clients, we view them more as partners in our collaborative efforts to develop, refine and validate cGMP-compliant processes to produce plant-made proteins.
Since 2010, KBP has collaborated with R.J. Reynolds Tobacco Company, another subsidiary of Reynolds American Inc., to explore new uses for the tobacco plant in existing and emerging tobacco-product platforms. That relationship led to RAI’s acquisition of KBP in January 2014.
Later in 2014, KBP received international media attention for the work it was doing to produce experimental monoclonal antibodies to treat the Ebola virus infection. Information about that work has been reported by a variety of media outlets, including reports on CBS’s 60 Minutes and the PBS NewsHour.